Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant + Radiotherapy in Older Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT05724602Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of xevinapant in head and neck squamous cell carcinoma (HNSCC), sponsored by European Organisation for Research and Treatment of Cancer. Started Nov 2023; status: terminated.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05724602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724602.